Friday, 15 September 2017

Tesaro's ovarian cancer drug gets EU agency backing

(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)